Amgen (Belgium)

Recent papers from Amgen (Belgium)

1. Metabolism of New Drug Modalities Research Advances – 2024 year in reviewDrug Metabolism Reviews · 2025
2. Converging evidence for a “gray‐zone” of amyloid burden and its relevanceAlzheimer s & Dementia · 2020
3. The Healthcare Professionals’ Perspective on Impact and Actions Taken Following Severe Infusion Reaction Events in Oncology Centers in EuropeDrugs - Real World Outcomes · 2020
4. European follow-up of incorrect biomarker results for colorectal cancer demonstrates the importance of quality improvement projectsVirchows Archiv · 2019
5. Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRCAdvances in Therapy · 2019
6. Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study resultsActa Clinica Belgica · 2019
7. Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?Annals of Hematology · 2017
8. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin LymphomaPharmacoEconomics · 2016
9. Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS RegistryThe Journal of Rheumatology · 2011